---
title: "ANKE BIO: The \"AK2017 Injection\" is expected to initiate Phase III clinical trials in early next year"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/263229091.md"
description: "On October 28th, ANKE BIO stated during an institutional research that the clinical trial progress of its independently developed \"AK2017 Injection\" is going smoothly, having completed the enrollment for Phase II clinical trials. It has now submitted a supplementary application for Phase III clinical trials and is expected to initiate Phase III clinical trials at the beginning of next year"
datetime: "2025-10-29T07:28:20.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/263229091.md)
  - [en](https://longbridge.com/en/news/263229091.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/263229091.md)
---

# ANKE BIO: The "AK2017 Injection" is expected to initiate Phase III clinical trials in early next year

ANKE BIO stated during an institutional research on October 28 that the clinical trial progress of its independently developed "AK2017 Injection" is going smoothly, having completed the enrollment for Phase II clinical trials. It has now submitted a supplementary application for Phase III clinical trials, which is expected to start in early next year

### Related Stocks

- [300009.CN](https://longbridge.com/en/quote/300009.CN.md)

## Related News & Research

- [Lytix Biopharma Advances Ruxotemitide Program as Q1 2026 Results Underscore Oncology Focus](https://longbridge.com/en/news/287162474.md)
- [15:55 ETInception Fertility Launches MySpermBank, Expanding Access to Donor Sperm Services Nationwide](https://longbridge.com/en/news/287265370.md)
- [New York Governor Signs Bills To Preserve Mandatory Vaccines](https://longbridge.com/en/news/286947583.md)
- [09:35 ETOpen Medicine Launches Ahead of ASCO, Introducing "Living Algorithms" for Real-Time Oncology Decision-Making](https://longbridge.com/en/news/286923155.md)
- [New report highlights gap between New GMO hype and global market reality](https://longbridge.com/en/news/287257766.md)